VolitionRx Limited Unrealized Gain (Loss) on Derivatives
VolitionRx Limited (VNRX) reported Unrealized Gain (Loss) on Derivatives of $943.46 thousand for the 3-month period ending 2014-12-31, per its 10-K filed 2016-03-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2016-03-11
- VolitionRx Limited unrealized gain (loss) on derivatives for the quarter ending 2014-12-31 was $943.46K.
| Period end | Unrealized Gain (Loss) on Derivatives 2 month | Unrealized Gain (Loss) on Derivatives 3 month |
|---|---|---|
| 2014-12-31 | -$143.27K 10-K · filed 2016-03-11 | $943.46K 10-K · filed 2016-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |